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Abstract
Background—In sub-Saharan Africa, there are limited data on the incidence of sexually 
transmitted infections (STIs) among women, largely because routine screening for asymptomatic 
infection is not performed. We conducted a secondary analysis to measure STI incidence rates and 
determine risk factors for new STI acquisition among women enrolled in the VOICE trial.
Methods—We analyzed data from 4843 women screened for chlamydia, gonorrhoea, syphilis, 
and trichomonas infection at baseline, annually, at interim visits when clinically indicated and at 
their study termination visit. Risk reduction counseling and condoms were provided throughout 
the trial.
Results—Twenty percent of evaluable participants had one or more curable STIs at baseline. 
Over 5660 person-years at risk (PYAR) of observation, incidence rates were 13.8% (95% 
confidence interval [CI], 12.7–14.8) PYAR for chlamydia, 3.5% (95% CI, 3.0–4.1) PYAR 
gonorrhea, 0.1% (95% CI, 0.6–1.1) PYAR syphilis, and 6.6% (95% CI, 5.8–7.2) PYAR 
trichomoniasis. South African sites had the highest incidence of chlamydia. The Uganda site had 
the highest incidence of gonorrhoea and syphilis, and Zimbabwe the lowest incidence overall. The 
majority of these cases were diagnosed at a routine scheduled testing visit. In multivariate 
analysis, positive baseline STI, younger than 25 years, being unmarried, and some alcohol 
consumption were associated with acquiring a new STI.
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Conclusions—We observed high rates of STIs during follow up among women in the VOICE 
study. Women living in human immunodeficiency virus endemic countries should be screened for 
common STIs.
The burden of sexually transmitted infections (STIs) remains high, affecting an estimated 
340 million people globally each year.1 The presence of curable STI (chlamydia, 
gonorrhoea, syphilis, trichomoniasis) and other reproductive tract infections is associated 
with multiple adverse reproductive health outcomes that include pelvic inflammatory disease 
(PID), infertility, chronic pelvic pain,2 and a 2-fold to 3-fold increased risk of human 
immunodeficiency virus (HIV) acquisition.3,4 The majority of incident STI infections occur 
in developing countries including those in the Sub-Saharan Africa region that is the 
epicenter of the HIV pandemic. The current HIV pandemic is fueled by uncontrolled rates of 
STIs and other reproductive tract infections in the same communities.
Evaluating the impact of global STI prevention and control programs requires quality 
surveillance data that remain largely inadequate in developing countries due to lack of 
capacity.2 Current efforts to contain the spread of STIs including HIV rely on interventions 
that aim to reduce risky sexual behavior and provision of condoms, along with screening and 
treatment of STIs.5 In low resource settings, women who present with symptomatic vaginal 
discharge are treated under the guidelines of “syndromic management” based on presenting 
symptoms and clinical judgment, in absence of identified etiological organism. These 
guidelines typically recommend empirical anti-microbial coverage for suspected pathogens 
using World Health Organization–recommended flowcharts.6 However, syndromic 
management fails to detect the large majority of STIs which are asymptomatic. Among 242 
HIV uninfected women enrolled in Durban, South Africa, and followed up for 2 years, only 
12% of women having a laboratory-diagnosed STI (gonorrhoea, chlamydia, trichomoniasis) 
were symptomatic, suggesting that reliance on syndromic management misses more than 
80% of STIs in women.7
The VOICE study provided an opportunity to measure prevalence of STIs at baseline and 
follow-up among women who were provided risk reduction counseling and condoms 
throughout the duration of the trial. This secondary analysis aimed to evaluate STI burden 
and determine common risk factors in the presence of risk reduction counseling and condom 
provision within the scope of a clinical trial.
MATERIALS AND METHODS
Study Design and Participants
We analyzed prospective data from the VOICE trial (MTN-003) a randomized, placebo-
controlled trial that investigated the safety and effectiveness of oral and topical tenofovir 
based preexposure prophylaxis for prevention of sexually transmitted HIV in women. 
Women aged 18 to 40 years were enrolled by targeting areas associated with high-risk 
behaviors “hot spots” such as night clubs, beerhalls, overcrowded resettlement (high density) 
areas and locations with marginalized populations from Uganda, Zimbabwe and South 
Africa from 2009 to 2011 and followed up until 2012. Women were scheduled to be 
followed up for a minimum of 12 months and a maximum of 34 months. Eligibility criteria 
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required that participants be HIV-uninfected, sexually active, nonpregnant, free of curable 
genitourinary infection, and willing to use effective contraception (oral contraceptive pills, 
injectable progestins, implantable devices containing progestins, intrauterine devices, or 
sterilization).8 Women were not eligible if they reported allergy to latex condoms, were 
within 6 weeks of delivery or planning to get pregnant during follow-up. As has previously 
been reported, adherence to the VOICE study drugs was low, and no regimen significantly 
reduced HIV acquisition compared to placebo.8
Procedures
Participants provided written consent. Research ethics committees and institutional review 
boards in Zimbabwe, Uganda, South Africa, and the United States approved the VOICE 
trial.
Behavioral assessment interviews using standardized questionnaires were administered 
monthly to document number of sexual partners, frequency of intercourse, condom use, 
intra-vaginal practices and contraceptive use. Sensitive questions, like those assessing report 
of anal intercourse and alcohol use, were asked via audio computer-assisted self-interview at 
quarterly visits. Human immunodeficiency virus testing, pregnancy testing, and study 
product management were performed at monthly visits. All participants received a 
comprehensive HIV prevention package that included ongoing risk reduction counseling and 
provision of male and/or female condoms at each monthly visit throughout the trial.
Participants were screened for chlamydia, gonorrhea, syphilis, and trichomoniasis at 
baseline, annually, when clinically indicated and at their study termination visit. STI 
treatment was provided on-site. During the pelvic examination, a speculum was inserted, 
naked eye inspection for cervical-vaginal discharge, superficial lacerations, ulcers, and 
collection of specimens for diagnosis of genital infections were performed. Urine samples 
were collected for pregnancy tests and for screening for Chlamydia trachomatis and 
Neisseria gonorrhoeae. Participant's partners were offered HIV testing, STI screening, and 
treatment. Potential participants with curable STI and other genitourinary infections (except 
for asymptomatic candidiasis) diagnosed at screening were eligible for enrollment after 
completing treatment per World Health Organization guidelines. Consistent with local 
standards, test of cure was not performed routinely.
Laboratory Testing
A vaginal swab was used to perform the OSOM® Rapid Trichomonas (Sekisui Diagnostics, 
San Diego, Calif) test for Trichomonas vaginalis. Saline wet mount of a vaginal smear was 
examined onsite among women reporting symptoms for candidiasis; if clue cells or motile T. 
vaginalis was noted in the vaginal fluid, these were reported. Syphilis serology was 
performed first by rapid plasma reagin (RPR) with positives being titered and confirmed by 
treponemal-specific assay (TPHA or TPPA). Testing for HIV followed a protocol-defined 
algorithm. The Determine HIV 1/2 (Alere Diagnostics, Orlando FL, USA) and either the 
Oraquick (Orasure Technologies, Bethlehem, Pa) or Uni-Gold Recombigen HIV (Trinity 
Biotech PLC, Wicklow, Ireland) were performed on whole blood or EDTA plasma samples 
for initial HIV testing. All HIV positive samples were confirmed by a Genetic Systems 
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Western Blot (Bio-Rad Laboratories, Redmond, Wash). Herpes simplex virus type 2 
(HSV-2) status at baseline, and exit was determined by central testing using the FOCUS EIA 
(Focus Technologies, Cypress, Calif).
The Strand Displacement Amplification by BD Probe Tec ET (Becton Dickinson, Franklin 
Lakes, NJ) system was used to test for C. trachomatis and N. gonorrhoeae from urine 
samples. Pregnancy status was ascertained with monthly urine hCG testing using the 
QuickVue One-Step or Combo kit (Quidel, San Diego, Calif).
Because women in the study could be randomized to oral tablets or vaginal gel products, all 
STI test systems and pregnancy tests were evaluated to ensure that the vaginal gel products 
did not interfere with test performance prior to the initiation of the study.
Statistical Methods
Data forms from each site were faxed to the Statistical Center for HIV/ADIS Research and 
Prevention for processing. Incidence rates were calculated as the number of incident events 
(allowing for multiple events per participant) divided by the total person-years at risk 
(PYAR). Results are presented as number of events/100 PYAR. The variance of the 
confidence interval (CI) was calculated based on methods by Stukel et al.9 Because women 
with STIs and other genital infections at all sites received effective treatment, chlamydia, 
gonorrhea, and trichomoniasis infections detected during the follow-up period were regarded 
as new infections unless a positive result was within 10 days of a previous positive result. 
For data analysis of syphilis, a positive RPR test with a titer greater than 0, and a positive 
confirmatory test was considered as positive. All positive RPR test results from baseline 
were included. During follow-up, new syphilis infections were determined if no previous 
infection was reported or if the participant had adequate treatment for a previous syphilis 
diagnosis and had a 4-fold increase in titer from the previous event, and the titer was at least 
8.
To assess associations between STI acquisition and study arm and between STI acquisition 
and baseline risk factors, a generalized estimating equation (GEE) method was employed. 
The baseline factors used in these analyses are summarized in Table 1. The GEE models use 
the Poisson distribution, a log link, an exchangeable correlation structure and follow-up time 
as the offset. All models, except for those assessing the risk by country, were adjusted by 
site. In the multivariable GEE models, backward selection was used to retain only the factors 
significant at the 0.05 level in the final adjusted model. All statistical analyses were 
performed using SAS 9.4 (SAS Institute, Inc., NC).
RESULTS
Among 5029 participants enrolled in the VOICE study, 164 (3%) participants had no testing 
for any of the curable STIs after enrollment, and another 22 (<1%) were found to be HIV 
positive at baseline and excluded from this analysis, leaving 4843 (96%) evaluable 
participants who contributed 5660.6 PYAR of follow-up for this analysis. Of the 164 
participants excluded from the analysis, 63 (38%) withdrew from study, 58 (35%) were lost 
to follow-up, 30 (18%) relocated, 9 (5%) terminated at the scheduled exit visit before and/or 
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with a missed annual testing visit, and 4 (2%) terminated for other causes including death 
and investigator decision.
Selected baseline and demographic risk factors by country are summarized in Table 1. The 
average age was 25.4 years. The majority of participants 3824 (79%) were unmarried with 
1078 (22%) reporting 1 or more partners in addition to their primary sex partner. At least 
some alcohol consumption was reported by 1266 (26%) of women and 1046 (24%) reported 
sex without condoms in the last 7 days before that visit. Ugandan women reported the 
highest rates of some consumption of alcohol 188 (61%) of 310. Across all sites, 
participants reported a mean of 2.5 episodes of vaginal intercourse during the 7 days before 
enrollment,7 whereas 837 (18%) reported any anal sex in past 3 months. Ugandan and 
Zimbabwean women reported the highest rates of condomless sex, 133 (48%) of 277 and 
289 (48%) of 600, respectively.
Of the 4843 evaluable participants, 956 (20%) participants had one or more STIs at baseline, 
114 (12%) participants had 2 STIs and 14 (2%) had 3 STIs at baseline.
The baseline prevalence of STIs by country is displayed in Table 1.
A total of 1352 cases of STIs (763 chlamydia, 196 gonorrhea, 48 syphilis, 345 
trichomoniasis) were diagnosed during follow-up visits. The majority of these cases were 
diagnosed at a scheduled visit which included routine STI testing (91% of chlamydia, 88% 
gonorrhea, 96% syphilis, 69% trichomoniasis) rather than a visit at which new problems or 
symptoms were addressed. The number of STI and HIV events and the HIV incidence is 
displayed in Table 2. The incidence of STIs by all of the baseline factors is displayed in 
Table 3. During follow-up visits, 763 cases of C. trachomatis were reported, resulting in an 
incidence of 13.8 events/100 PYAR across all 3 countries, with South African sites reporting 
the highest incidence at 15.9 events/100 PYAR (Table 3). The highest HIV incidence (6.9 
events/100 PYAR) was also observed in the South African sites. Zimbabwean women had 
the lowest incidence rates of STIs and HIV (0.8/100 PYAR). Ugandan women had the 
highest incident rates of gonorrhea (5.9 events/100 PYAR) and syphilis (4.0 events/100 
PYAR), trichomoniasis (7.4/100 PAYR) and low HIV incidence (2.1/100 PYAR).
Among the participants who tested positive for each of the STIs during follow-up, a 
significant percentage had tested positive for the same STI at screening (baseline) before 
study enrollment. Because these participants were treated for the infection before enrolling 
in the study, these infections during follow-up most likely represented new infections. 
Chlamydia and gonorrhea test results were available at baseline and follow-up for 4789 
participants. Of those participants, 577 (12%) had chlamydia at baseline and 174 (30%) of 
577 had a repeat chlamydia infection during follow-up. For gonorrhea, 154 (3%) tested 
positive at baseline and 15 (10%) of 154 had a repeat gonorrhea infection during follow-up. 
Of the 4781 participants with baseline and follow-up syphilis test results available, 67 (1%) 
had syphilis at baseline and 8 (12%) of 67 had a repeat syphilis infection during follow-up. 
Of the 4572 participants with baseline and follow-up trichomoniasis test results available, 
277 (6%) had trichomoniasis at baseline, and 71 (26%) of 277 had a repeat trichomonas 
infection during follow-up.
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After adjusting for site, we identified a number of independent risk factors for acquisition of 
STIs during follow-up (Table 4). Having an STI at baseline was the strongest predictive risk 
factor for incident infection with any of the 4 STIs during follow-up. Trichomoniasis was 5.6 
times more likely to be diagnosed during study follow-up when it was present at baseline. 
Syphilis was 6.8 times more likely to be diagnosed during follow-up when present at 
baseline, whereas chlamydia and gonorrhea were twice as likely to be diagnosed during 
follow-up when present at baseline. Younger age and marital status were also important risk 
factors for incident STIs, with participants younger than 25 years being twice as likely and 
unmarried participants being 1.5 times more likely to acquire chlamydia. Diagnosis of 
gonorrhea was also twice as common in women younger than 25 years, but was also 70% 
more likely in women who consumed some alcohol. Trichomoniasis was more likely to 
occur in participants who were positive for HSV-2 at baseline. There were no significant 
differences in STI incidence rates in the active product arms compared with placebo arms.
DISCUSSION
In this subanalysis of women who participated in the VOICE study, we observed a high rate 
of curable STIs during follow-up among women who were provided ongoing risk reduction 
counseling and free condoms throughout the trial. Critically, and of importance for 
consideration of implementation of routine STI screening in such women, the vast majority 
of these infections were detected at routinely scheduled visits not visits prompted by 
symptoms. A significant number of these cases were diagnosed among women who received 
treatment after testing positive at screening, thus implying that most of these cases 
represented repeat infections rather than treatment failure. However, although routine partner 
treatment was offered in this study, no data were collected to capture the number of partners 
who were not successfully treated, nor was a test of cure performed after treatment to ensure 
that there was high adherence to STI treatment medications.
The STI incidence rates were highest at South African sites that also recorded the highest 
HIV incidence rates. Women younger than 25 years had the highest incidence rates for both 
curable STIs and HIV. Study retention in the VOICE was high at 91%,8 thus most 
participants would have received ongoing risk reduction counseling and also collected their 
condom supply during scheduled visits. Despite this provision, high-risk sexual behaviors 
were common as evidenced by high rates of curable STIs. Negotiating condom use among 
women in these male-dominated communities remains a challenge as reported in several 
studies.10 The provision of testing for STIs at baseline, annually, and when clinically 
indicated provided us opportunity to accurately determine the frequency of STIs among 
high-risk women in low resource settings where syndromic management of STIs is the 
standard of care.
Our study supports the observation that a significant number of women with laboratory 
confirmed STIs are likely asymptomatic and therefore will miss the opportunity to be 
offered treatment using current syndromic management recommendations in low resource 
settings.7,11 In this population with a high number of repeat infections during follow-up, 
untreated cases may progress and cause a significant future burden in reproductive morbidity 
that includes chronic pelvic pain, infertility and ectopic pregnancy. Chlamydia is associated 
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with 16% progression to PID in untreated women followed up prospectively.12 In HIV-
negative women, presence of STIs increases susceptibility of HIV by recruiting HIV pro-
inflammatory cells to genital epithelium and disrupting mucosal barriers,3,4,13 a major 
concern that impedes current progress for HIV control in sub-Saharan Africa. Gonorrhea 
and chlamydia both facilitate HIV transmission; therefore, control of these treatable STIs as 
part of a HIV combination prevention strategy is essential. In this subanalysis of data from 
the VOICE study, we estimate that only a small proportion of women who tested positive for 
chlamydia, gonorrhoea, syphilis, or trichomoniasis were symptomatic at time of diagnosis, 
because the majority tested positive at routine scheduled testing visits.
We identified several independent risk factors associated with recurrent curable STIs among 
women enrolled in the VOICE study. Even though participants with baseline STIs comprised 
a small percentage of participants with the same STI during follow-up, having a curable STI 
at baseline remained the strongest predictive risk factor for being diagnosed with the same 
STI type (not necessarily the same organism) during follow-up (Table 4). The high baseline 
STI prevalence presumably reflects underlying community burden of preventable infections. 
We were however unsuccessful in reducing high-risk behaviors in this population as 
evidenced by the high incidence of the four types of STIs during follow-up. A limitation of 
our study analysis is the long duration between study visits resulting in potential likely 
underestimates of STI incidence. However, the associations we observed should remain 
valid as diagnostic testing was done consistently throughout the study. In the absence of a 
test of cure for diagnosed STIs, we are not able to determine if some of the incident cases 
were from treatment failure or reinfections from untreated partners.
To have an impact on STIs and HIV in young women, there is an urgent need to develop 
innovative interventions which incorporate sexual and reproductive health promotion and 
evaluation of new vaccines.14 In many high-income countries, there is evidence of a decline 
in pelvic inflammatory disease observed after implementing annual programs to screen and 
treat chlamydia and gonorrhea among women younger than 25 years.15,16 Randomized 
controlled trials have confirmed that screening and treatment for C. trachomatis can prevent 
pelvic inflammatory disease.16–18 Nucleic acid amplification tests with high sensitivity 
(>90%) and high specificity (>90%)16 are now available as rapid tests that can be 
implemented in programs suitable for point of care testing for chlamydia, gonorrhea and 
trichomoniasis.19,20 There is an urgent need for validation of accurate easy to use point of 
care tests in low resource settings that will result in more timely targeted treatment and 
earlier partner management.21 Our data strongly support a recommendation to transition 
from syndromic management to targeted annual and repeat testing for STIs among high-risk 
young women living in HIV endemic communities. Moreover, the high rate of repeat 
infection speaks to the lack of partner management services available in these settings. 
Implementing feasible and affordable tests in screening programs for chlamydia and 
gonorrhea, along with partner management, should accelerate control of STI in these women 
at high risk for HIV acquisition. Evidence of improved uptake of STI screening through 
integrated services for STI/HIV in health care facilities like family planning, postnatal and 
STI clinics speaks to the potential of this approach in targeting women in the years of 
reproductive health.22
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TABLE 1
Baseline Demographics and Baseline Curable STIs Among Evaluable Participants
All Countries South Africa Uganda Zimbabwe
Evaluable participants 4843 3918 310 615
Age
  Mean (SD) 25.4 (5.2) 24.7 (5.1) 28.2 (4.8) 28.1 (4.7)
  Min, max 18.0, 40.0 18.0, 40.0 19.0, 40.0 18.0, 39.0
  < 21 y 918 (19%) 872 (22%) 17 (5%) 29 (5%)
  21–24 y 1536 (32%) 1357 (35%) 60 (19%) 119 (19%)
  25–30 y 1514 (31%) 1118 (29%) 127 (41%) 269 (44%)
  > 30 y 875 (18%) 571 (15%) 106 (34%) 198 (32%)
Currently married 1019/4843 (21%) 271/3918 (7%) 169/310 (55%) 579/615 (94%)
No. partners in addition to primary sex partner
  0 3731/4809 (78%) 3033/3884 (78%) 121/310 (39%) 577/615 (94%)
  1 792 (16%) 691 (18%) 71 (23%) 30 (5%)
  2 157 (3%) 108 (3%) 43 (14%) 6 (1%)
  3 or more 129 (3%) 52 (1%) 75 (24%) 2 (<1%)
Education: primary school or less 387/4839 (8%) 147/3914 (4%) 187/310 (60%) 53/615 (9%)
Children: 1 or more 4114/4842 (85%) 3198/3917 (82%) 303/310 (98%) 613/615 (>99%)
Earns own income 2792/4843 (58%) 2281/3918 (58%) 230/310 (74%) 281/615 (46%)
Alcohol consumption*: At least some 1266/4808 (26%) 1039/3883 (27%) 188/310 (61%) 39/615 (6%)
Any anal sex (in the past 3 mo) 837/4773 (18%) 767/3854 (20%) 23/306 (8%) 47/613 (8%)
Any vaginal sex without condoms in past 7 d† 1046/4403 (24%) 624/3526 (18%) 133/277 (48%) 289/600 (48%)
HSV-2–positive 2210/4834 (46%) 1817/3909 (46%) 196/310 (63%) 197/615 (32%)
Baseline curable STIs
  Chlamydia 584 (12%) 550 (14%) 18 (6%) 16 (3%)
  Gonorrhoea 155 (3%) 131 (3%) 17 (5%) 7 (1%)
  Syphilis 67 (1%) 42 (1%) 20 (6%) 5 (1%)
  Trichomoniasis 292 (6%) 230 (6%) 22 (7%) 40 (7%)
  Any of these STIs 956 (20%) 827 (21%) 67 (22%) 62 (10%)
*
Participants indicated any amount of alcohol consumption in contrast to never drinking alcohol.
†
Includes the participants who completed the questions on the Baseline Behavioral Assessment form regarding any vaginal sex in the past 7 days 
and the number of times a condom was used. If participants had vaginal sex in the last 7 days and used a condomless than 100% of the time they 
are included in this category as having unprotected sex (without condoms) in the 7 days.
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TABLE 2
Curable STIs and HIV Events During Follow-Up
All Countries South Africa Uganda Zimbabwe
Evaluable ppts 4843 3918 310 615
Chlamydia
  ppts with chlamydia test follow-up after enrollment 4790 3871 310 609
  Total follow-up time: PYAR 5543.7 4299.8 424.1 819.8
  Total no. chlamydia events during follow-up (ppts) 763 (659) 685 (590) 41 (38) 37 (31)
Gonorrhoea
  ppts with gonorrhoea test follow-up after enrollment 4790 3871 310 609
  Total follow-up time: PYAR 5543.7 4299.8 424.1 819.8
  Total no. gonorrhoea events during follow-up (ppts) 196 (179) 162 (149) 25 (21) 9 (9)
Syphilis
  ppts with syphilis test follow-up after enrollment 4781 3862 310 609
  Total follow-up time: PYAR 5533.0 4289.7 423.8 819.6
  Total no. syphilis events during follow-up (ppts) 48 (47) 29 (28) 17 (17) 2 (2)
Trichomoniasis
  ppts with trichomoniasis test follow-up after enrollment 4577 3667 299 611
  Total follow-up time: PYAR 5230.5 4001.7 406.9 822.0
  Total no. trichomoniasis events during follow-up (ppts) 345 (300) 266 (232) 30 (27) 49 (41)
HIV*
  ppts with HIV test follow-up after enrollment 4842 3917 310 615
  Total follow-up time: PYAR 5453.7 4205.7 422.0 826.0
  No. ppts with HIV seroconversion 307 291 9 7
  Incidence rate (per 100 person-years) 5.6 6.9 2.1 0.8
  95% CI for incidence (5.0–6.3) (6.1–7.8) (1.0–4.0) (0.3–1.7)
*
HIV results include follow-up time up to seroconversion since there are not multiple events per participant. In addition, HIV events are included 
only for the participants with STI test follow-up. Therefore, these results may be slightly different than the results given in the VOICE primary 
article.8
ppts, participants.
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TABLE 4
Multivariable Models* With Baseline Risk Factors for Curable STIs
Chlamydia Gonorrhoea Syphilis Trichomoniasis
Participants included in the model 4789 4754 4781 4563
Baseline STI status†: positive versus negative
  IRR (95% CI) 2.1 (1.8–2.5) 2.1 (1.3–3.5) 6.8 (2.8–16.7) 5.6 (4.3–7.3)
  P <0.001 0.005 <0.001 <0.001
Age: < 25 y vs ≥ 25 y
  IRR (95% CI) 2.2 (1.9–2.6) 2.3 (1.6–3.2) — —
  P <0.001 <0.001 — —
Marital status: unmarried versus married
  IRR (95% CI) 1.5 (1.1–2.1) — — —
  P 0.024 — — —
Alcohol consumption: some versus none
  IRR (95% CI) — 1.7 (1.2–2.3) — —
  P — 0.003 — —
Baseline HSV-2: positive vs negative
  IRR (95% CI) — — — 1.6 (1.2–2.0)
  P — — — <0.001
*
Complete list of variables available in Table 3.
†
The baseline STI status is from the same STI that is being modeled. (e.g. in the Chlamydia column, baseline STI status refers only to Chlamydia 
test results).
—, not retained in the final multivariable model since the factor is not significant at the 0.05 level; IRR, incident rate ratio.
Sex Transm Dis. Author manuscript; available in PMC 2017 July 31.
